Correspondence: Refractory epidermolysis bullosa acquisita: Successful treatment with rituximab

Clinical and Experimental Dermatology

Volumn 34, Issue 8, 2009, Pages

  Saha, M ^a   Cutler, T ^b   Bhogal, B ^a   Black, M M ^a   Groves, R W ^a  

^a ST THOMAS HOSPITAL   (United Kingdom)

^b IPSWICH HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIBIOTIC AGENT; AZATHIOPRINE; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; DAPSONE; IMMUNOGLOBULIN; IMMUNOGLOBULIN G; METHYLPREDNISOLONE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISOLONE; RITUXIMAB; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY;

ADULT; CASE REPORT; CELLULITIS; DRUG EFFECT; DRUG MEGADOSE; EPIDERMOLYSIS BULLOSA ACQUISITA; FEMALE; HUMAN; HUMAN TISSUE; IMMUNOBLOTTING; LEG ULCER; LETTER; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS INFECTION; MULTIPLE CYCLE TREATMENT; PHYSICAL EXAMINATION; PRIORITY JOURNAL; SEPSIS; SKIN BIOPSY; TREATMENT RESPONSE; MIDDLE AGED; TREATMENT OUTCOME;

ANTIBODIES, MONOCLONAL; EPIDERMOLYSIS BULLOSA ACQUISITA; FEMALE; HUMANS; IMMUNOLOGIC FACTORS; MIDDLE AGED; TREATMENT OUTCOME;

EID: 72549118002     PISSN: 03076938     EISSN: 13652230     Source Type: Journal    
DOI: 10.1111/j.1365-2230.2009.03608.x     Document Type: Letter

References (5)

1. Schmidt E, Benoit S, Brocker E-B et al. Successful adjuvant treatment of recalcictrant epidermolysis bullosa acquisita with anti-cd20 antibody rituximab. Arch Dermatol 2006 142 : 147 150.
2. Crichlow SM, Mortimer NJ, Harman KE. A successful therapeutic trial of rituximab in the treatment of a patient with recalcitrant, high-titre epidermolysis bullosa acquisita. Br J Dermatol 2007 156 : 194 196.
3. Neidermeier A, Eming R, Pfütze M et al. Clinical response of severe mechanobullous epidermolysis bullosa acquisita to combined treatment with immunoadsorption and rituximab (anti-CD20 monoclonal antibodies). Arch Dermatol 2007 143 : 192 198.
4. Schmidt E, Hunzelmann N, Zillikens D et al. Rituximab in refractory autoimmune bullous diseases. Clin Dermatol 2006 31 : 503 508.
5. Nagel A, Podstawa E, Eickmann MM et al. Rituximab mediates a strong elevation of B-cell-activating factor associated with increased pathogen-specific IgG but not autoantibodies in pemphigus vulgaris. J Invest Dermatol 2009 doi :, Mar 12 (Epub).